High SAMHD1 levels indicate poor clinical response to nucleoside analogues such as cytarabine, decitabine, and nelarabine in acute myeloid leukaemia (AML), acute lymphoblastic leukaemia, and Hodgkin lymphoma [36, 39, 41, 50]. This evidence concerns the gene SAMHD1 and acute lymphoblastic leukemia.